Sari Laitinen

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Orion Pharma Oy provides contract manufacturing services to the pharmaceutical sector. Its services include sterile, solid forms, liquid forms, semi-solid forms, hormone, and anti-cancer production, primary as well as secondary packaging, and testing. The company is headquartered in Espoo, Finland.

LZ Therapeutics, Inc. develops novel differentiated products for the treatment of neurological disorders. It provides therapeutics to improve patient outcomes, including improved symptom control and potential disease modification. The company was founded by Jay S. Schneider in 2005 and is headquartered in Chester, PA.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.